Background and Significance: Although known to effectively provoke large scaled weight-loss, less is known regarding age-and sex-related influences on treatment outcomes of bariatric patients treated with a very-low calorie diet (VLCD) program. Purpose: This study retrospectively examined body composition and metabolic changes induced by a 12-wk proprietary VLCD treatment in obese patients while assessing age and sex differences. Methods: Male (n=16) and female (n=16) patients underwent 12 weeks of VLCD under standard medical care. Results: Older patients exhibited a greater relative loss of FFM compared to younger patients (p=0.004). Older patients also lost a greater proportion of total weight-loss as FFM (p=0.003) and lower proportion as FM (p=0.003) compared to the young group. This age-specific difference in weight-loss composition was driven by the older males. Conclusion: The results demonstrate the need for special clinical considerations for VLCD treated patients, such as older adults and perhaps older males specifically, who demonstrate a reduced quality of weight-loss compared to their younger counterpart.
Introduction
Epidemiological findings from the National Health and Nutrition Examination Survey (NHANES 2011 (NHANES -2014 reported that just over 36% of U.S. adults are currently classified as obese, while 16% represent incidences of severe cases (Ogden, Carroll, Fryar, & Flegal, 2015) . Obesity reflects a prevalence rate far exceeding the threshold of 15% set by the World Health Organization (WHO) for epidemics needing intervention (Flegal, Carroll, Kit, & Ogden, 2012) . In fact, a recent comprehensive analysis indicated that in 2015, high body mass index (BMI) contributed to 4.0 million deaths globally (7.1% of deaths) which represents a 28% increase from 1990 (Collaborators, 2017) . A high BMI also accounted for 28.6 million years lived with disability (3.6% of all cause of disability) (Collaborators, 2017) . Hence, national health initiatives have prompted the urgency for effective clinical treatments to reconcile the global spread of obesity and subdue the heightened socioeconomic burdens directly attributable to this epidemic (Ogden et al., 2015) .
Despite the methodological advancement in treatment options, such as surgical-or pharmacological-based approaches, medically supervised weight-loss programs incorporating hypocaloric dietary modifications have remained an ongoing and widely prescribed therapy for obesity (Tsai & Wadden, 2005) .
Amongst hypocaloric approaches, proprietary very low calorie diet (VLCD) programs (~800 kcal/day), e.g. Optifast ® (Nestlé HealthCare Nutrition), have been medically prescribed as a purportedly viable option for high-risk patients whose body mass index (BMI) exceeds 30 kg/m 2 , or exhibit critical mortality risk, or have failed to respond favorably to conventional and unmonitored weight-loss programs.
VLCD prescriptions, which are based mostly on liquid meal replacement formulas, have been consistent with outcomes of revitalized health with significant body weight (BW) reductions ranging between 15-27% in obese subjects (Donnelly et al., 1993; Tsai & Wadden, 2005; Wadden & Frey, 1997; Walsh & Flynn, 1995) . This loss in total body mass, however, cannot be solely accounted for by reduced adiposity, but also significant deficits in FFM, especially for the highly metabolically active skeletal muscle (Bryner et al., 1999; Chaston, Dixon, & O'Brien, 2007; Donnelly, Jakicic, & Gunderson, 1991; Donnelly et al., 1993; Eston et al., 1992; McIver, Wycherley, & Clifton, 2012) . A meta-analysis revealed a positive correlation between the loss of FFM and degree of energy restriction (r 2 = 0.31, p=0.006), supporting the contention that a hallmark manifestation of VLCD treatment is a greater loss of FFM compared to less restrictive approaches (e.g. low calorie diet, LCD). In fact, a recent study showed that VLCD treated subjects lost a greater proportion of their weight as FFM compared to LCD treated subjects (Vink, Roumans, Arkenbosch, Mariman, & van Baak, 2016) . Mitigating this reduction in FFM during intentional rapid weight-loss, as induced by VLCD, is of particular significance in older adults, in order to avoid a potential exacerbation of age-related loss of lean mass (sarcopenia), which may lead to profound debility and impaired quality of life. Therefore, the purpose of this retrospective study was to determine the effects of age and sex on weight-loss dynamics in VLCD-treated obese patients. (two-compartment model) were measured at the TMH Bariatric Center using an FDA-approved medical body composition analyzer (Tanita TBF-310; Arlington Heights, Illinois, USA) that is equipped with a BW scale and bioelectrical impedance analysis (BIA) capabilities. The analyzer provided computed measurements for BW, BMI, body fat percentage (BF%), fat mass (FM), and lean mass as fat free mass (FFM) (i.e. FFM = BW -FM); the FFM compartment includes lean soft tissues plus bone mineral content. Percentage of FFM of total BW (FFM%) was extrapolated from BIA data. Waist circumference (WC) was measured through a previously described protocol (Berk et al., 2012) . BW and BMI were recorded each week during the 12-week treatment period. Body composition and anthropometric variables, i.e. FM, FFM, BF%, FFM%, and WC, were measured once pre-and post-treatment. The body composition analyzer demonstrated good reliability with a test re-test coefficient of variation of 1.6%.
Methods

Study Design and Participants
Metabolic Panel. Lipid panels included values for total cholesterol, triacylglycerol (TAG), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL). Other metabolic tests included fasting blood glucose levels as well as hemoglobin A1c (HbA1c) values. All measures were obtained in the 8-hour fasted state. Systemic metabolic profiles were measured preand post-treatment.
Statistical Analyses
All data are presented as mean ± standard error (SE). All descriptive variables were analyzed using a dependent student t-test for baseline comparisons between sexes and between agegroups. Pre-and post-treatment measurements for body composition, anthropometric, and metabolic biomarkers were analyzed using a 2 (sex) x 2 (age) x 2 (time) repeated measures ANOVA. Relative change from pre-to posttreatment for all dependent variables were calculated and analyzed by a 2 (sex) x 2 (age) multifactorial ANOVA. In the event of a significant main effect or interaction, a Tukey post hoc test was used for pairwise comparisons. All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) with significance set at p<0.05.
Results
Body Composition
There was a significant change from pre-to post-treatment for all body composition and anthropometric variables when examining the sample in aggregate as well as in individual sex and age cohorts (Tables 2-4). There were no significant differences between sexes for the pre-to post-treatment reductions in BW (p=0.61), FM (p=0.10), FFM (p=0.17), BMI (p=0.61), or WC (p=0.31) ( Table 3 ). The relative pre-to post-treatment change in BW (p=0.94), FM (p=0.27), WC (p=0.28), or BMI (p=0.91) was equivalent between age-groups (Table 4) . However, the old-group demonstrated a greater relative loss in FFM than the young-group (p=0.004). There was a sex by age interaction for the relative pre-to post-treatment loss of (FFM (p=0.013), while no interaction was detected for all other measures (Table 5) . Post hoc analysis revealed that older males relatively lost more FFM than younger males (p=0.0003). There were no differences in relative FFM-loss between female age cohorts (p=0.72). Further, younger females lost more FFM, relatively, than younger males (p=0.008) while, in the older cohort, there were no differences between sexes for the relative loss of FFM (p=0.39). 
Contributions of FM-and FFM-Loss to Total Weight-Loss
The proportion of total weight-loss due to changes in FM and FFM differed across sexes, age-groups (Figure 1a) , and sex-age cohorts (Figure 1b) . Specifically, the percentage of total weight-loss attributed to reductions in FM was greater for the young-group (81.4±3.7% of total weight-loss) compared to the old-group (64.8±4.1% of total weight-loss) (p=0.003). Also, the percentage of total weight-loss attributed to loss of FFM was lower for the young-group (18.7±3.7% of total weight-loss) compared to the old-group (35.0±4.1% of total weight-loss) (p=0.003). The proportion of weight-loss due to reductions in FM and FFM was not different between sexes. However, a sex by age interaction showed that the proportion of weight-loss due to FM-loss was greater for young-males (90.5±3.5% of total weight-loss) versus old-males (61.8±6.3% of total weightloss) (p=0.002) (Figure 1b) . Also, FFM-loss accounted for a greater proportion of total weight-loss in old-males (38.3±6.3% of total weight-loss) compared to young-males (9.7±3.4% of total weight-loss) (p=0.002) (Figure 1b ).
Blood Metabolic Profile
There was a significant time effect for HbA1c, fasting glucose, total cholesterol, TAG, and VLDL. From pre-to post-treatment, there was a decrease in HbA1c (-13.5±2.7%; p=0.0009), fasting glucose (-8.5±2.7%; p=0.01), total cholesterol (-8.9±2.7%; p=0.004), TAG (-21.2±4.6%; p=0.001), and VLDL (-20.1±6.7%; p=0.02). There was a sex effect for change in HbA1c as males demonstrated a greater decrease than females pre-to post-treatment (-18.0±4.3% vs. -7.3±1.5%; p=0.04). There were no sex or age effects for pre-to-post changes in all other metabolic panel variables.
Discussion
Overall, the VLCD-based treatment program produced, at least in the short-term, a clinically meaningful weight-loss as evidenced by a significant reduction in adiposity and overall improvement in metabolic profile. The total weight-loss exhibited by the aggregate patient group corroborates outcomes of similar VLCD interventions previously evaluated by Walsh and Flynn (1995) and Wadden et al. (1992) . Moreover, a majority of investigations reported that patients who successfully completed a comprehensive VLCD program (that included lifestyle modification) generally lost 15-25% of initial BW in 3 to 4 months (Anderson, Konz, Frederich, & Wood, 2001; Astrup & Rössner, 2000; Mustajoki & Pekkarinen, 2001; Saris, 2001; Tsai & Wadden, 2006) . The strength of the present findings, however, resides in the differential weight-loss dynamics due to age and sex. A favorable outcome for most weight-loss prescriptions is to maximize the reduction of FM while preserving or improving FFM. Lowered basal metabolic rate, neuromuscular deficits, undue fatigue, poor physical function, and increased risk for musculoskeletal injury have been reported to occur as a result of diminished FFM, especially during advanced aging (Arciero, Goran, & Poehlman, 1993; Donnelly et al., 2009; Finer, Swan, & Mitchell, 1986; Nelson, Weinsier, Long, & Schutz, 1992; Ravussin et al., 1988; Tsai & Wadden, 2005) . Any of these factors taken together with the dramatic loss of FFM would be conducive to impeded fat reduction, weight recidivism, and relapses of prior health complications (Stiegler & Cunliffe, 2006) . Because of the clinical significance of decreased FFM, weight-loss treatments incorporating VLCD or other aggressive modes of dietary modifications remain controversial. The weight-loss composition with a VLCD is approximately 75% due to FM-loss and 25% due to FFM-loss (Bray et al., 2012; Weinheimer, Sands, & Campbell, 2010) which agrees with outcomes of our overall patient cohort. Interestingly, our findings demonstrate the observed weight-loss composition to be significantly affected by age and sex, revealing the limitations and controversies of current VLCD programs that generally fail to consider these evidentially influential factors.
Specific findings of interest include age-related outcomes in weight-loss composition as opposed to simply total BW reduction. Total absolute weight-loss following the 12-week treatment was comparable between age groups (-17.3% for young and -17.1% for old), which may lead to misguided perceptions that VLCD treatments yield equivalent benefits among younger and older patients. However, from a body composition and perhaps weight-loss quality standpoint, our findings suggest that VLCD outcomes are indeed distinct between young and old patients. Our data show that older patients lose about 17% less FM and 58% more FFM than their younger counterparts, thereby offsetting any age-related differences in total weight-loss. As presented in Figure 1a , the proportion of weight-loss from FM-loss decreases with age while FFM-loss becomes increasingly contributory. These age-specific effects on FM-and FFM-loss indicate that advancing age may negatively affect the quality of overall weight-loss when induced by VLCD and perhaps other modes of severe dietary restriction. This of course is based on the contention that good weight-loss quality is defined as a significant reduction in FM without compromising FFM. Based on the observed divergence in weight-loss patterns between age groups, the matter of sarcopenia emerges as an important clinical issue especially considering the surmounting population of obese older adults (Goisser et al., 2015) .
As a critical manifestation of advanced aging and obesity, previous literature supports the presence of a condition in which obese older adults demonstrate a reduced FFM to BW ratio, poor skeletal muscle quality, impaired physical function, and increased systemic inflammation (Bollheimer et al., 2012; Roubenoff, 2004; Schrager et al., 2007; Thornell, 2011; Zamboni, Mazzali, Fantin, Rossi, & Di Francesco, 2008) . This condition has been collectively termed sarcopenic-obesity, which is fundamentally the coexistence of age-related muscle wasting and excessive adiposity (Zamboni et al., 2008) . Consequently, the proper clinical approach to obesity treatment for older adults becomes an immense challenge due to the adverse effects of severe caloric restriction on FFM as evidenced by our current findings. In other words, it may be reasonable to suggest that weight-loss therapies, such as VLCD, exacerbate the sarcopenic progression for older adults. Our results are corroborated by a systematic review of 52 studies that examined age-specific changes in BW and FFM in response to a variable period of energy restriction (Weinheimer et al., 2010) . When evaluating weight-loss composition, 50% of their older study cohorts lost more than 25% of their BW as FFM. Moreover, intentional weight-loss, even when excess adipose tissue is targeted, also includes accelerated skeletal muscle loss which is inversely associated with functional capacities for autonomous living in older adults (S. L. Miller & Wolfe, 2008) . Collectively, sarcopenic-obesity renders a complex issue for medical practitioners who need to prescribe an appropriate weight-loss treatment that moderates the health risks related to obesity while also preserving muscle to minimize the severity of sarcopenia. Based on our findings, these considerations appear more critical for older male patients who evidently demonstrate greater relative loss in FFM compared to their younger counterparts (Table  5) , ultimately manifesting in inferior weight-loss quality (Figure 1b ). These responses are intriguing when considering the previous reports indicating the morphological and functional manifestations of sarcopenia to be more severe in men than women (Finer, 2001; Finer et al., 1986; Finkelstein, Fiebelkorn, & Wang, 2003; Iannuzzi-Sucich, Prestwood, & Kenny, 2002) . Our comprehensive evaluation of age-specific responses confirms the need to restructure the current VLCD-based programs to better optimize weight-loss characteristics for older adults due to the aforesaid issues. Our findings stress the importance for healthcare professionals to thoroughly evaluate the risks and benefits of VLCD prescriptions especially for older adults and tailor treatment programs accordingly. This leads us to the question of how VLCD systems, like Optifast ® , can be enhanced through practical interventions.
As others have noted, exercise continues to be a key component of successful dietary weight-loss endeavors (Arciero, Baur, Connelly, & Ormsbee, 2014; Arciero et al., 2006; Bryner et al., 1999; Johannsen et al., 2012; Longland, Oikawa, Mitchell, Devries, & Phillips, 2016) . As discussed by Miller et al. (2013) , exercise affects a wide range of physiological, behavioral, and psychosocial variables, which in most cases are considered more positive than negative for the weight-loss patient. For instance, Villareal et al. (2011) showed a 21% improvement in physical performance test scores when energy restriction was combined with formal exercise training, while the absence of exercise resulted in only a 12% increase. Also, exercise training, mostly aerobic, has been previously scrutinized as a means of enhancing weight-loss composition and/or resting metabolic rate during dietary restriction in obese participants but has shown equivocal outcomes (Bamman et al., 2001; Donnelly, Pronk, Jacobsen, Pronk, & Jakicic, 1991; Fine et al., 1999; Hammer, Barrier, Roundy, Bradford, & Fisher, 1989; Hill, Sparling, Shields, & Heller, 1987; Pavlou, Steffee, Lerman, & Burrows, 1985) . Resistance training, more specifically systematic and periodized resistance training, has been less examined despite its known potency in promoting anabolic adaptations in skeletal muscle. Further, typical VLCD systems and treatment programs fail to integrate sophisticated and structured applications of exercise assumingly due to the limited availability and translation of data to properly guide medical practitioners.
Another area of concern is the relative protein content of VLCD. Previous findings suggest that the custom protein composition of the Optifast ® system is rather inadequate especially if combined with a resistance training intervention. For instance, the current study cohort at a mean initial BW of 131 kg would consume a VLCD providing only 0.5 g of protein/kg bodyweight/day. Thus, VLCD formulations like Optifast with a protein dose of 70g/day would fall below the RDA of 0.8 g/kg/day. Metaanalyses suggested that higher-protein consumption of approximately 1.2 g/kg/day promotes greater LM maintenance than diets lower in protein (<0.7 g/kg/day) under weightloss circumstances, particularly when combined with resistance training (Krieger, Sitren, Daniels, & Langkamp-Henken, 2006; Weinheimer et al., 2010) . In fact, Pasiakos et al. (2013) showed that consuming 2-3 times above the RDA protein intake lowers the relative contribution of LM-loss to the total weight reduced during energy restrictive periods. Therefore, the RDA for protein intake, and thereby customary Optifast ® protein content, remains insufficient for the preservation of LM, especially for the average 131 kg patient. Based on mean BW data from the current study, in addition to the aforesaid protein recommendation (1.2 g/kg/day), approximately 150 g of protein per day would be required for the maintenance of LM during a VLCD intervention. In a recent study by Longland et al. (2016) , a higher protein intake of 2.4 g/kg/day compared to 1.2g/kg/day yielded superior outcomes for LM as well as FM during an energy deficit combined with resistance training. These findings along with the present provide excellent support for the combined implementation of higher protein intake and resistance training in VLCD or hypocaloric treatment programs for obesity.
The most noteworthy contribution of the current study is that proprietary weight-loss systems can be evaluated and translated in a scientifically apt manner. We expect our report to enable both the patient and practitioner a better opportunity to assess the risk and efficacy of proprietary VLCD programs with information beyond what is commercially advertised. We also anticipate our current investigation to act as a model for the medical nutrition industry to systematically evaluate dietary weight-loss products through scientifically sound research with complete transparency with their findings. As in the pharmaceutical industry, product evaluations and reporting should be mandated within the nutrition industry to prevent falsified or misleading advertising, which unfortunately has become quite pervasive.
Overall, our findings demonstrate the considerable need for treatment optimization as it pertains to the post-VLCD management of BW and adiposity. Given the supported health benefits of VLCD-induced weight-loss for the severely obese, it becomes an imperative goal to generate post-treatment conditions that would minimize the chance for a patient to relapse into unhealthy weight-gain. Patients generally regain 40 to 50% of BW lost approximately one to two years post-VLCD, especially in the absence of follow-up care (Tsai & Wadden, 2006; Wadden, Foster, Letizia, & Stunkard, 1992; Wadden & Frey, 1997) . Based on our current assessment of the 12-week Optifast ® program, patients experience a reduction in FFM, which in certain cohorts, i.e. old males, is presented more severely than others. Because the preservation of FFM, metabolic rate, and physical function plays a critical role in the long-term maintenance of healthy weight status, practical interventions (i.e. resistance training, protein modifications) with large potential to address these factors should be integrated into VLCD-based treatment plans. Overall, our findings from this investigation support the need for the clinical integration of structured exercise training and protein modifications with the purpose of 1) optimizing weight-loss composition as well as metabolic and functional outcomes; and 2) promoting lifestyle modifications conducive to healthy weight status and long-term management.
